Tom Nolan’s research reviews—19 November 2021

#### No surprises for Pfizer The phase II/III double-blind randomised controlled trial of Pfizer’s BNT162b2 vaccine in 5-11 year olds has been published in NEJM.1 It contains another classic covid incidence-versus-time graph, where the placebo arm ascends like an alpine pass and the BNT162b2 arm has the gentle ascent of a stroll in Norfolk. The authors report a vaccine efficacy of 90.7% for preventing symptomatic covid-19, when two 10 µg...